Introduction
The morbidity and expense associated with chronic ulcers of the lower extremities are well known.' The limitations of current therapy despite numerous and varied approaches as well as attempts at understanding aetiology and natural history make this a subject of continued interest. As the complex biological process of wound healing becomes better understood, the importance of peptide growth factors and their receptors has become more apparent and their potential role as therapeutic agents in these nonhealing wounds has become a real possibility. In vitro studies and animal model testing of many growth factors have shown promising results. There have been some early clinical trials with growth factors in chronic wounds which suggest a potential therapeutic role. We will give a brief overview of current knowledge concerning relevant growth factors and their potential use in the treatment of chronic leg ulcers.
Growth fectors: en overview
The term 'growth factor' encompasses a group of diverse peptides displaying a wide and varied range of actions on cells. The first member of this group to be isolated was nerve growth factor in 1952. Over the last decade there has been a virtual explosion of knowledge in this field. It has become increasingly clear that growth factors play roles of paramount importance in directing the behaviour of cells in processes as diverse as fetal development, oncogenesis, disease states such as atherosclerosis, and wound healing (reviewed in ref. 2) . Much progress has also been made in studying the various growth factor receptors and the 'downstream' changes occurring within the cell after receptor-ligand interaction. The response to this physical interaction is known to be both cell type and growth factor specific. The response cascade typically begins with autophosphorylation of the receptor itself on a tyrosine, serine or threonine residue. This exposes domains on the receptor which are then able to interact with defined sequences on cytoplasmic effector molecules (e.g. the so-called SH2 domains). This is the beginning of a chain reaction of activation and deactivation of many different molecules within the cell. Depending on the desired end result, many of these molecules and pathways are common for different growth factor-receptor reactions. Binding kinetics, differential quantitative responses and posttranscriptional modifications may all play roles in the case of common response pathways. The final steps for many of these pathways take place inside the nucleus. Genes encoding intranuclear transcription factors such as myc, [os and jun are activated; their products interact with defined spatial sequences of DNA to either stimulate or suppress transcription of certain genes. The end result is proliferation, chemotaxis, differentiation and/or production of growth factors The scope of this article does not allow for appropriate treatment of this subject. Interested readers are directed to literature which discusses the current status of growth factor molecular biology.e-'
The various stages of normal wound healingthe inflammatory phase, the granulation tissue deposition phase, and the remodeling phase are thought to be directed in large part by growth factors. Although much attention has focused on platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-13), epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF), other identified agents not yet used in clinical trials have been demonstrated in various animal models to be highly active in tissue repair (Table 1) . Again, the interested reader is directed to review articles on this subject.S?
Healing deficiencies of chronic wounds
The rationale supporting the treatment of chronic wounds with exogenous growth factors is that there is, for some reason, an effective deficiency of the appropriate growth factor in and around the wound. Therefore, in addition to accepted principles of optimal debridement and cleaning, oedema control, pressure relief, and tissue oxygen delivery, growth factors offer the promise of pharmacologically accelerating or stimulating healing.
Tissue hypoxia-growth factor interactions
Local tissue ischaemia with resultant hypoxia profoundly impairs wound healing. Ischaemia plays a role in both arterial insufficiency as well as venous insufficiency. 7 Diabetic patients may also exhibit significant cutaneous ischaemia in the lower extremities." The effects of hypoxia on growth factor actions is important. With the utilization of an ischaemic wound healing model, our laboratory is presently testing the efficacy of topical growth factors in combination with hyperbaric oxygen. In our rabbit ischaemic dermal ulcer model the combination of TGF-I3, PDGF or bFGF with a daily treatment protocol of hyperbaric oxygen at two atmospheres resulted in total restoration of the wound healing deficit. 9 Hyperbaric oxygen by itself had a minimal effect, and growth factors alone only partially restored the wound healing deficit under these ischaemic conditions. bFGF had a complete lack of efficacy in this ichaemic model, but its effectiveness was restored by adding intermittent hyperbaric oxygen. These results are interesting because of the obvious clinical applicability. They also highlight the importance of multimodality therapy.
Venous ulcers: fibrin cutTsand the 'trap' hypothesis
A unified theory of the pathophysiology of venous ulcers remains speculative. One popular theory is based upon the presence of pericapillary fibrin cuffs believed to form secondary to prolonged venous hypertension and distension of cutaneous capillary beds.'? These pericapillary fibrin deposits may act as barriers to the movement of oxygen and nutrients to dermal tissue. However, there is evidence that ulcers heal despite the persistence of these fibrin cuffs. 11 The recently advanced 'trap' hypothesis of venous ulceration suggests that macromolecules such as fibrinogen and alpha-2-macroglobin leak into the dermal matrix in the presence of venous insufficiency. Once in position, these macromolecules could bind growth factors and essential nutrients, thereby effectively preventing them from reaching their appropriate target.P Although there are no direct experimental data to support this hypothesis, it is appealing because it suggests that sufficient exogenous growth factor could overwhelm the trapping and improve healing.
Another proposed explanation for the chronic nature of venous ulcers involves white blood cellmediated endothelial damage stemming from the pooling of blood in the extremities of people with chronic venous insufficiency.P There is experimental evidence supporting this idea.r-The proteases found in chronic wound fluid may be released from these excess white blood cells trapped in the affected tissue.i> and may degrade endogenous growth factors thereby creating a local growth factor deficiency. Exogenous growth factors would also potentially be damaged by these proteases. Interestingly, many growth factors are thought to be relatively proteaseresistant, based upon their structure. Nevertheless, the potential for degradation of growth factors, both endogenous and exogenous, does exist.
Wound fluid
Analysis of wound fluid has been used recently by several investigators to study the microenvironment of the wound. Clear differences exist between acute (healing) and increased extracellular matrix degradation in these wounds.'? Additionally, there is increased protease activity as well as inhibitory agents in chronic wound fluid compared to acute or healing wound fluid. 15,20 As stated above, this suggests that active inhibition of wound healing may work by degradation of biologically active cytokines and/or their receptors. The exact nature of these 'inhibitors' remains unknown.
Epithelialization
In many chronic wounds, epithelialization seems to be the critical interrupted step. Clinical experience confirms that despite vigilance and aggressive therapy, chronic ulcers often proceed to the stage of healthy granulation tissue formation yet fail to epithelialize. Cultured skin allografts have been suggested as a temporary biological dressing, and with the use of neonatal cells they are thought to promote epithelialization by expression and modulation of important cytokines and growth factors,21,22 Keratinocyte cultures are known to produce multiple growth factors in vitro. The success of skin grafts in the treatment of chronic ulcers may lie in their ability to effectively deliver or stimulate resident cells to deliver growth factors such as EGF, TGF-a and VEGF (vascular endothelial growth factor) to the appropriate target as well as providing a biological dressing. Although some initial trials Table 2 Selected human trials utilizing this strategy have been promising, further confirmation of these results has not been forthcoming.
Human growth factor studie.
An assumption of current clinical growth factor therapy is that topical application of growth factors should be efficacious. Growth factors in general have a very short biological half-life when given systemically and this approach has not been used in animal models except for a few notable exceptions. 23, 24 In the case of several growth factors, including PDGF and TGF-~, sustained release from a collagen vehicle as opposed to a saline solution is important in terms of activity;25,26 The optimal pharmacokinetics for growth factor therapy are still largely unknown. The vehicle in which they are applied may be important. EGF has been shown to be ineffective when applied for only a short interval or delivered as a miSt. 27, 28 Human trials with growth factors have begun only recently. Results from some of the completed studies are discussed below (see Table 2 ).
Epidermal growth factor (EGF)
The first major study of growth factor efficacy in humans involved topical EGF applied to splitthickness skin graft donor site wounds in bum victims.s? Although the results are not directly applicable to chronic wounds, the study was well designed and executed and showed a definite effect. Their long-term follow-up confirmed no hyperplasia or malignancy at the treatment sites. Histological analysis confirmed that the dermis returned to normal after termination of treatment, suggesting that topical growth factors (specifically EGF) can be an effective and safe form of therapy.
In an open-label crossover study of various types of chronic wounds, eight of the nine wounds healed completely in an average of 34 days of treatment with a topical EGF-silver sulphadiazene cream.w This was after a minimum of three weeks of treatment with silver sulphadiazene alone during which time these wounds showed no evidence of healing. Seven of the nine wounds were on lower extremities, of which six healed. Aetiologies included diabetes, burns, and rheumatoid arthritis. Because this was only a phase I trial, the only real conclusion that can be drawn is that further testing is warranted. A randomized double-blind study of topical recombinant EGF compared to placebo showed that there was no significant improvement in the treated venous ulcer group after a ten-week trial.I! A trend in favour of the 35 treated patients was noted but was not statistically significant. Of note, the favourable results of the placebo group in this study reinforce the importance of aggressive wound care, patient education and vigilance in treating these wounds.
Platelet-derived growth factor (pDGF) PDGF has been most comprehensively studied in the treatment of pressure sores. A phase I study in 1992 suggested its potential benefit in this type of wound.V A recent phase II study of elderly patients with pressure ulcers showed that four weeks of daily treatment resulted in an average 54% greater decrease in wound volume when compared to placebo-treated wounds (p = 0.009).33 David Steed of the University of Pittsburgh reported a beneficial and statistically significant effect on wound closure in a multicentre, prospective, randomized, doubleblind trial involving patients with diabetic ulcers treated daily with PDGF for 20 weeks (presented Theory ofgrowth factors and ulcer healing 83 at FDA Meeting on Chronic Wounds, Washington, DC, April 1993).
Basic fibroblast growth factor (bFGF)
A study using bFGF to treat pressure ulcers also resulted in a statistically significant decrease in ulcer volume among the treatment group wounds.>' Although the pathophysiology of chronic pressure ulcers differs from that of chronic leg ulcers, once established, many of the factors involved in maintaining them may not be so different. For example, chronic infection probably plays some role in both pressure and diabetic ulcers.V Experimental animal data suggest that bFGF may decrease bacteria counts in chronic wounds and accelerate wound contraction.w A presumed mechanism is increased granulation tissue and activated inflammatory cells within the wound. If this is true then any chronic wound could potentially benefit from the actions of exogenous bFGF. Of note, a recent clinical study of bFGF in non-healing leg ulcers was terminated by the sponsor (Synergen) because of lack of clinical efficacy. 37 Human growth hormone (hGH)
Human growth hormone (hGH) has been studied with respect to its utility in chronic leg ulcers. Although not strictly a growth factor, hGH is a peptide cytokine. Animal testing suggests that it works by stimulating tissue production of IGF-I (insulin-like growth factor).3!! In a study using daily topical hGH or placebo for an average of eight weeks, the treated ulcers showed both a greater rate of healing and a greater reduction in overall size.l? No long-term results were presented. This work has yet to be repeated.
Platelet-derived wound healing formula (PDWHF)
Platelet-derived wound healing formula* (PDWHF) has been tested primarily in chronic non-healing leg wounds. PDWHF is an autologous or pooled homologous preparation made from human blood using a standard protocol. 40 PDWHF has been shown to contain multiple growth factors, most notably PDGF and TGF-J3. The formula is applied topically to the wound after cleaning. Results with PDWHF in chronic lower extremity wounds have been mixed. A double-blind, crossover, randomized study using autologous PDWHF on various types of leg ulcers resulted in 81% complete epithelialization in the treatment group compared to 16% in the control group." The majority of wounds were diabetic and venous stasis-related. Unfortunately, not all studies have produced positive results. 42.43 There has been substantial debate over the results of these studies.v' The ultimate answer may only come from a large, prospective, multicentre, randomized trial.
Conclusions
A major problem of studying the potential clinical role of growth factors is the absence of a true animal model for chronic non-healing ulcers. Ischaemia, diabetes and irradiation models do exist but they cannot incorporate the dermal and subdermal changes seen histologically in chronic wounds. Human testing is the only reliable option.
Application of multiple growth factors to a single wound is an option which deserves further exploration. In principle this would allow for both synergy and redundancy in the system whereby individual variations are compensated for by excess of more than one growth factor. Animal studies have demonstrated the potential benefits of combined growth factor application, specifically PDGF with IGF-I or bFGF.45.4 6 The problem of non-healing wounds is an old one that continues to challenge physicians. A poor understanding of the pathophysiology combined with moderate success using any of today's accepted therapies make patients with chronic wounds of the lower extremities a frustrating and frustrated population with which to deal. Growth factor research is a fascinating and fast-growing field. Human trials have begun and are providing interesting and encouraging results. We have outlined the results of some clinical trials as well as difficulties inherent in studying a subject as complex and heterogeneous as chronic wound healing. To date, most of the human growth factor trials have required combining multiple aetiologies into the same test group thereby hampering interpretation of the results. The heterogeneity seen in human wounds does not exist in animal models and therefore animal testing does not allow for accurate extrapolation to use in humans. Only further human testing will help to answer these questions. Although growth factor therapy holds exciting promise in the future, its ultimate therapeutic role remains to be defined. Cost-benefit analysis will need to be done at some point. It is possible that less expensive stimulators of endogenous growth factor production (inflammatory stimulants) may be more beneficial. Growth factors are a long way from becoming the panacea for problem wounds, but they do offer the potential of becoming a real addition to the physician's armamentarium for dealing with a problem which continues to plague modern medicine.
